Published in Lab Business Week, July 22nd, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Vasogen Inc..
Report 1: Vasogen Inc. (NASDAQ:VSGND; TSX:VAS) announced a collaboration with Grupo Ferrer Internacional, S.A. ("Ferrer"), a leading European pharmaceutical and medical devices company, to commercialize Vasogen's Celacade(TM) technology for the treatment of chronic heart failure in the European Union and in certain Latin American countries. Under the agreement, Vasogen will receive 45% of Celacade revenues generated by Ferrer, as set out below, for a period five years from the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.